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Abstract
We deal with a small enough tumor section to consider it homogeneous, such that popu-
lations of lymphocytes and cancer cells are independent of spatial coordinates. A stochastic
model based in one step processes is developed to take into account natural birth and death
rates. Other rates are also introduced to consider medical treatment: natural birth rate
of lymphocytes and cancer cells; induced death rate of cancer cells due to self-competition,
and other ones caused by the activated lymphocytes acting on cancer cells. Additionally,
a death rate of cancer cells due to induced apoptosis is considered. Weakness due to the
advance of sickness is considered by introducing a lymphocytes death rate proportional to
proliferation of cancer cells.
Simulation is developed considering different combinations of the parameters and its
values, so that several strategies are taken into account to study the effect of anti-angiogenic
drugs as well the self-competition between cancer cells. Immune response, with the presence
of a kind of specialized lymphocytes, is introduced such that they appear once cancer cells
are detected. Induced apoptosis of cancer cells is introduced to model the action of several
drugs under development right now. Besides, the model predicts the cancer relapse even
from a very small number of cells. Simulation is done by using Gillespie algorithm.
Keyword: Noise; mathematical models; cancer; tumors.
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I. INTRODUCTION
The basic goal of this paper is to present a computer simulated model to study the
population time evolution of two interacting species: cancer cells and lymphocytes, both
confined in a very small tumor, such that spatial dependence does not need to be considered.
Several strategies to attack the disease are simulated and two important conclusions are
reached: the first one, the efficiency is enhanced with a combination of anti-angiogenic
drugs plus a system based in artificial apoptosis of cancer cells; and the second one, a small
amount of cancer cells are enough for the reappearance of the disease.
Efforts to capture in a mathematical model the dynamic of chemical substances and cells
involved in the development of cancerous tumor started, at least, since 1955 with a work
about the cell structure of lung cancer under radiotherapy [1]. After 1980 the amount of
papers dealing with cell dynamics related to cancerous tumors rose significantly (See for
example [2–5]).
At first, a set of cancerous cells is an avascular tissue, without blood vessels, and its
dimension is just a few millimeters. Due to the lack of nutrients, the internal shells of
the tumor die, then, a segregation of chemical substances produce vasculogenesis in the
neighborhood of the small tumor, such that new vessels appear connecting it with the
cardiovascular system. Once that food is available, the tumor grows to be an encapsulated
tumor or a malignant one with capacity to spread to neighboring organs. This is known as
metastasis.
Vascularization produces layers that randomly raise a barrier to block drugs introduced
inside the body to destroy cancerous cells. So, the application of chemical substances be-
comes a spatial process where diffusion through a chaotic tissue is very hard because the
administered drug must survive for internal mechanism used by living tissues disintoxicate
themselves. For this reason, it is difficult to penetrate a solid tumor preserving the level of
toxicity needed to kill cancerous cells [6].
Models to mathematically understand this problem has been directed to several goals.
One of these is to understand how a cytotoxic substance jumps the barrier to reach cancerous
cells [7]. Another one is to study the volumetric growth of the tumor after the action
of chemotherapy and surgery [8]. If someone is going to develop a mathematical model
to study tumors, a good advice is to take into account the classification presented by T.
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Roose et. al. [9]. They say that there are three different stages for cancer development:
avascular, vascular and metastatic. In the second one the tumor has blood vessels, while
in the first one has not. Once that there is enough blood, solid tumors changes a lot
of his properties and show several pathological features. They are disorganized and its
vasculature does not work. In this cases mathematical models based on spatial diffusion
processes are needed (see for example Eugene J. Koay et. al.[10]) Besides, new approaches
have been introduced to predict the size of tumors based on the mitotic/apoptotic index
and on diffusion penetration [11]. In the same sense, Jennifer Pascal et. al. have proposed a
model based in a differential equation of diffusion inside the tumor, obtaining a biophysical
description of the vascular/tissue architecture and drug perfusion within the malignant zone
[12]. In summary, metastatic stage appears when cancer cells spread from the tumor to
other parts of the body. Models for avascular tumors are considered as a first step toward
building models for vascularized tumors. On the other hand, one should consider that when
cancer cells are in a high nutrient environment they proliferate, but in low nutrient levels
they die. Besides, there is an intermediate period called quiescent in which nutrient levels
do not permit proliferation but cancer cells stay alive. Since any tumor needs blood to grow,
a lot of research to find how to stop angiogenesis (the process of building new blood vessels
from the surrounding body to the tumor) has been done. The nature of initial considerations
can be seen at [13]. So, in 2008 Shaked et. al. [14] reached the conclusion that clinical trials
have indicated that drugs that inhibit the growth of blood vessels can sometimes enhance
the effectiveness of traditional chemotherapy. For example, simultaneous administration of
the antiangiogenic drug bevacizumab with the chemotherapeutic agent paclitaxel improves
survival benefits for metastatic breast cancer and small cell lung cancer. This kind of
combined strategy suggests that it would be a good strategy to combine chemotherapy with
antiangiogenic drugs.
Based on these findings, we simplify our problem dealing with a tumor before metastasis,
so that population does not depend on spatial coordinates. As a consequence, it is possible
to work with a model based in computer simulations with birth and death probabilities
whose mathematical form takes into account the number of cells acting in a small volume.
This approach is similar to the one consisting of working with particles in statistical physics
to get thermodynamics, fluctuations and out of equilibrium phenomena, including systems
with few particles like that of nanostructures. In a previous paper [15] we used the same
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hypothesis to develop an analytical stochastic model where treatments based on chemother-
apy were considered, and the same mathematical approach can be generalized to deal with
antiangiogenic drugs, including a kind of artificially induced apoptosis in cancer cells. Two
coupled and nonlinear differential equations were found to describe the temporal evolution
of the average density of cancer cells and lymphocites. Numerical solutions were obtained
to explore the dynamical behavior of the system. The existence of two basins was found in
that paper: one where the patient survives (health basin) plus other where he dies. Just
as medical evidence show us. However, by studying the random behavior around the deter-
ministic values, a possible noise-induced escape from health basin was detected, because by
evaluating the eigenvalues of the involved matrices, it can be found that random fluctuations
have unbounded standard deviations, suggesting that disease could appear again. However,
just linear noise was considered because the analytical approach is based on van Kampen
omega expansion, and that kind of phenomena cannot be studied. A similar problem ap-
pears if we want to deal with small populations. Therefore, we have developed the present
approach to explore that problem and to simulate the combination of treatments based on
different strategies.
This paper is organized as follows: a model of the interaction between lymphocytes and
cancer cells is presented in the second section to estimate conditions needed to consider a
stationary situation, such that the number of both populations have the same number of
individuals. Our attention is paid on very small tumors (or a patch of a big one) to maintain
independence of spatial coordinates. A brief discussion about rate growth for cancer cells
and lymphocytes is presented in the third section to explain how the basic parameters were
selected. The model and the construction of transition rates is presented in the fourth sec-
tion, and also a summary of a first analytical approach developed by the authors is included
to show why computer simulations are needed to go ahead in the understanding of the
problem. Section five is devoted to present the Gillespie algorithm, such that a reader with
some experience can reproduce this work. Computational results are presented in the sixth
section, and also the development with the absence and the presence of specialized defense is
considered and compared. On the other hand, the effect of many no specialized lymphocytes
is considered to explore what happen if the process of maturity of lymphocytes does not
give the tools to identify cancer cells. Besides, strategies based on antiangiogenic drugs are
studied too. Results about released patients, declared free of disease under macroscopic con-
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siderations, are shown to explain that it is true that random fluctuations have unbounded
standard deviations which can produce a patient suffers a relapse. A combined strategy,
such that antiangiogenic and artificially induced apoptosis in cancer cells, is discussed to see
that results are better, preserving a better condition of patients. Finally, conclusions are
presented.
II. MATERIALS AND METHODS
In order to determine the size and the number of individuals to take into account in
the simulation, we consider the picture given by Macklin et. al. [16]. They say that an
avascular tumor can reach only a few micrometers of diameter when it is feeding from the
natural blood vessels of the near region of the organism. By simulating the development of
a tumor, they found that a quiescent core forms at about 9 days, when the tumor radius
is approximately 0.34mm, while a necrotic core appears around day 15 when the radius of
tumor is approximately 0.5mm. Therefore, to deal with a lower bound, in this paper we have
considered a small tumor, such that its radius is just rT ' 200µm = 0.2mm. We assume
that this tumor has a very small central core of necrotized tissue due to the absence of blood
irrigation. At this stage of the tumor development, the available blood vessels are just the
usual density of capillaries in a healthy tissue, without any addition in capacity to irrigate
that part. When the amount of blood is not enough, the cancer cells start to die due to the
shortage of oxygen and nutrients. At the same time the pressure executed by the growing
tumor on the surrounding healthy tissue destroys the extracellular matrix and changes the
normal flux of blood. Previous to metastasis, cancer cells produce chemical substances such
that the body starts the production of new vessels going to the tumor, and once this goal
is reached, a new stage is initiated where cancer cells have a faster reproduction and their
growing number is warrantied. Our goal is to study the tumor before metastasis starts.
So, our model is developed by assuming several hypotheses: 1) there is a stage where
cancer cells are organized inside a small sphere, without the typical chaotic growth of a
tumor producing metastasis, such that cancer cells form a battle line waiting for lymphocytes
advancing against them through the normal vessels of the body. 2) It is assumed that no shell
exists yet, so that immune system of the body can reach the cancer cells to destroy them. 3)
Finally, surviving cells and destroyed extracellular matrix are not considered between cancer
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cells, such that they can be considered like little spheres inside the tumor.
Therefore, the estimation of the number of cells involved can be done by taking into
account geometric considerations. The volume of the blood inside some part of the body
can be estimated by using the next proportion: first, a human body weighting 85kg has an
average of 5 l of blood, so that we can assume that the percentage of blood in some place of
the tissue is of the order of c = 5
85
= 0.05882 4. On the other hand, the blood flow speed in
a body is such that at ”aorta” has an average of 40 to 50 cm
s
, while at capillaries is just as
slow as vblood = 0.03
cm
s
= 300µm
s
(see for example [17]). With this assumption, we will get a
superior bound for time to be estimated, because a study done by K. Yamauchi et. al. [18]
have shown that cells migration through capillaries is such that the minimum diameter to
allow migration is 8µm, with a speed of cancer cells approximated to 48.3µm
h
. In the quicker
cases, the biggest migration velocity was reached just by 20 cells with 13.2µm
h
.
Then, we consider a cylinder of area A and height h = vblood ∗ t containing a volume of
blood given by
Vblood = Avbloodtc (1)
The number of leukocytes in the volume Vblood can be found by considering that its average
density is
5 ∗ 109 leukocytes
l
≤ ρleu ≤ 1.1 ∗ 1010 leukocytes
l
. (2)
Once these considerations are done, we can formulate the next question: how many cancer
cells are in touch with lymphocytes? To know that, we choose a small spheroidal tumor
whose radius is rT , containing cancer cells with radius rc.
Figure 1
The cross section of the tumor presented to blood flow is a half of the total surface of the
sphere, Ac = 4pir
2
T , containing Nc malignant cells in its boundary in potential contact with
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blood. Since these cells present a half of their surface to the blood flow, we obtain that
Nc =
1
2
AT
1
2
Ac
=
1
2
(4pir2T )
1
2
(4pir2c )
=
(
rT
rc
)2
. (3)
Besides, we need to answer the next question: how many lymphocytes can be in touch with
cancer cells? This quantity is estimated by assuming that blood vessels going to the tumor
are inside a cylinder whose area is A = pir2T and its volume is given by
Vbody = Avbt, (4)
with t a time which be determined ahead. The volume of blood contained in this cylinder is
Vblood = (Avbt) c. (5)
The amount of lymphocytes in the cylinder is
Nlin = (Avbtc) ρleu. (6)
We consider a system whose initial conditions are Nlin (t = 0) = Nc (t = 0), so that
Avbtcρleu =
(
rT
rc
)2
(7)
and
t =
(
rT
rc
)2
Avbcρleu
. (8)
Since lymphocytes are present in the scenario as a component of blood flow, and we have
chosen to deal with an initial static situation at t = 0, we need to estimate the time t such
that both of the populations in competence are numerically equal.
Such estimation of the time t depends on the size of tumor and we have selected the
optimal scenario, the one where the state of evolution of the tumor can be detected in a
threshold where imaging based on magnetic resonance is in its better resolution. In addition
to that, we want to suggest a mechanism.
For example, we can propose periodic scanning of the chest of a woman, or the prostate of
a man, by using 1.5 Tesla MR scanner at a spatial resolution of 117× 117× 300µm [19] and
with micro-CT whose spatial resolution reach cubes with 100× 100× 100µm [20]. It would
be necessary a system to save and recover files with old and new images, and techniques to
compare them automatically. This can be done with software based on neural networks.
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Clearly, several approaches could be cited because work is being carried out to detect can-
cer. For example, multiparametric magnetic resonance imaging is considered as a promising
method for the detection of prostate cancer [21]. Besides, a planar type antenna is report-
edly a useful design for detecting a cancerous tumor of 5 mm in size, in the early stages of
development [22]. On the other hand, Barbara Blasiak et. al. [23] have published a recent
review where they discuss several applications of nanomaterials for early and specific cancer
detection and therapy. And so on. The important point here is that very small tumors
should be considered.
Figure 2
To estimate t we choose a tumor whose diameter is 200µm, and a typical cancer cell whose
radius is rc = 4µm. Then, the equation (3) gives us Nc = 625. If ρleu = 5× 109 leukocytesµ l we
get
t = 854. 28 s,
and with ρleu = 1.1× 1010 leukocytesµ l we obtain
t = 310.65 s,
so that the interval to get the assumed scenario is
310.65 s < t < 854.28 s .
This is of the order of 5 minutes to 14 minutes and 15 seconds. Since the more aggres-
sive cancer cells have a doubling time rate of two days, a stationary situation where it is
considered the same amount of cancer cells and lymphocytes is an acceptable option.
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In our model, extracellular matrix is considered just as an empty space to be occupied,
without taking into account that, due to its destruction by the tumor, it is active in delivering
nutrients to be used in the expansion of malignant cells.
A. Rate growth
1. Cancer cells reproduction speed
The potential doubling time is defined as the time necessary to double the number of
proliferating tumor cells. According to the reference [24], the index named as potential
doubling time (Tpot) is evaluated by using a linear regression such that a straight line is
fitted to write the number of cells N as follows:
N = A+BeKpt,
where Kp is named the rate constant of cell production.
The number of counted cells N (t1) = N1 and N (t2) = N2, with t2 > t1, are fixed as
follows N1 = 10
3 and N2 = 2× 103, so that Tpot = t2 − t1. Then, we have
Tpot =
1
Kp
log
(
2000− A
B
)
Taking A = 0, we write down
Tpot =
1
Kp
log (2)
The next data can be found in (see Table 1 at [24])
tumor line Origin Tpot days (*) Tpot days (**)
FaDu SCC of pharynx 2.0± 0.2 1.3± 0.1
HCT15 Human colon adenocarcinoma 2.5± 0.1 2.2± 0.1
STS26T Schwannoma (soft tissue sarcoma) 2.5± 0.2 2.4± 0.2
U87 Glioblastoma multiforme 3.9± 0.3 2.5± 0.2
SCC21 SCC 5.9± 0.3 2.9
HGL9 Glioblastoma multiforme 6.2± 0.3 3.9± 0.3
U251-MG Glioblastoma multiforme 7.5± 0.5 10.5± 1.4
Table 1
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where data marked with (*) are obtained with one of the methods described in the last
reference (named first method cytokinesis block), and data marked with (**) are found
by using another method explained in the same reference (named there as second method
IdUrd).
Then, we have evaluated the next data for the rate constant of cell production, Kp, based
in the expression: K = log(2)
Tpot
:
Tpot (days) Kp (days
−1)
1 0.693147
1.5 0.462098
2 0.346574
2.5 0.277259
3 0.231049
3.5 0.198042
4 0.173287
4.5 0.154033
5 0.138629
5.5 0.126027
6 0.115525
6.5 0.106638
7 0.099021
7.5 0.0924196
8 0.0866434
Table 2
Here, Kp plays the same role as the parameter b1 (to be introduced ahead). So, we have
assumed that an aggressive cancer tumor will be such that
b1 = 0.35
where one cell produces a new one each two days.
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B. Lymphocytes reproduction speed
According to reference [25]: ”In healthy, HIV-1 seronegative subjects, CD4+ T cells
had half-lives of 87 days and 77 days, respectively, with absolute production rates of 10
CD4+ Tcells
µ l
per day and 6 CD8+ Tcells
µ l
per day.”
Then, starting from 1, a sequence obtained by adding the number 6 during 77 times,
reaches the value 463. If we assume an exponential growth, it must be a transition rate b2
given by
b′2 =
1
77
log (463) = 0.0797107,
for CD4+ lymphocytes, while a sequence such that the number 10 is added 88 times give us
b′′2 =
1
88
log (881) = 0.0770575,
for CD8+ lymphocytes. Therefore, we have chosen the value
b2 = 0.078
for our simulations.
In normal conditions, a balance in the number of lymphocytes is found if it is assumed
that apoptosis is d2 = 0.078, too.
C. The model and a summary of a first analytical approach
1. How transition rates are built
Our model for the tumor is a space where there are Ω small boxes, with three categories
for them: empty, occupied by a cancer cell, and occupied by a lymphocyte; so that there
are M boxes occupied by lymphocytes, N boxes occupied by cancer cells, and Ω−M −N
empty boxes. This is a collection to be treated as a big recipient with Ω balls, with three
possible colors: a) a blue ball corresponds to an empty box, b) a white ball corresponds to
a lymphocyte, and c) a black ball corresponds to a cancer cell. Events to be considered are
classified in three groups: 1) to get just one ball, 2) to find two balls, and 3) to obtain three
balls from the big recipient.
We denote a white ball (lymphocyte) with the letter B, a black ball (cancer cell) as A,
and a blue ball (empty space) as E.
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• In the first group of events we have: B → E (death of a lymphocyte by apoptosis),
and A→ E (death of a cancer cell by artificial apoptosis).
• In the second group of events: B+E → B+B (birth of a lymphocyte), B+A→ B+B
(death of a cancer cell due to the presence of a lymphocyte, or specialized defense),
A + E → A + A (birth of a cancer cell), A + A → A + E (death of a cancer cell by
self-competence).
• In the third group we consider just one event: A + A + B → A + A + E (death of a
lymphocyte due to weakness of the patient).
All of the events can occur with transition rates denoted as:
• Death rate (apoptosis rate) for lymphocytes: d2, (B → E).
• Death rate (artificial apoptosis rate) for cancer cells: d1, A→ E.
• Birth rate for lymphocytes: b2, (B + E → B +B).
• Death rate for cancer cells; c12, B + A→ B +B.
• Birth rate for cancer cells: b1, A+ E → A+ A.
• Death rate (self-competence) for cancer cells: c11, A+ A→ A+ E.
• Death rate (weakness due to sickness) for lymphocytes: c21, A+A+B → A+A+E.
Transition rates are built by using elementary probability, they are presented in the right
column of the Table 3.
event transition rate
B → E d2MΩ
A→ E d1NΩ
B + E → B +B b2M(M−1)Ω(Ω−1)
B + A→ B +B c12 MNΩ(Ω−1)
A+ E → A+ A b1N(Ω−N−M)Ω(Ω−1)
A+ A→ A+ E c11N(N−1)Ω(Ω−1)
A+ A+B → A+ A+ E c21 N(N−1)MΩ(Ω−1)(Ω−2)
Table 3
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It will be seen ahead that the transition B + A → B + B is very important because it
involves death of a cancer cell due to the action of a lymphocyte. In this case there are two
actions in one, it is the substitution of one A-cell by a B-cell. So, the number N diminishes in
1, while the number M increases in 1. It is considered here as a specialized response modeling
the activation of the body defense system through a sequence of biochemical events, such that
this kind of white blood cell can identify specific antigens through a molecule named TCR.
It can recognize specific antigens and can act as a cytotoxic cell against specific malignant
cells in a tumor in a very lethal way. This is the reason to name it as specialized defense.
2. Analytical approach based on van Kampen expansion
In [15] we have developed an analytical model by defining population densities as
n =
N
Ω
= ψ +
1√
Ω
η, m =
M
Ω
= φ+
1√
Ω
ξ, (9)
with (ψ, φ) the deterministic part, and (η, ξ) the random noise. Besides, we separated each
transition rate in a way similar to the one presented now
DM = d2
M
Ω
= d2φ+
1√
Ω
d2ξ = ΩD
(1)
M +
√
ΩD
(0)
M . (10)
Thus, a van Kampen expansion was done and it was possible to separate the problem in
two of them. First, a deterministic one, where differential equations must be solved to
know (ψ (t) , φ (t)). Second, a time dependent Ornstein-Uhlenbeck stochastic process, whose
density probability function obeys a Fokker-Planck equation whose coefficients depend on
the statistical properties of 〈ψ〉 and 〈φ〉.
The general approach presented there gives us a pair of coupled ordinary differential
equations for the deterministic part of the problem
d 〈ψ〉
dt
= f
(〈ψ〉 , 〈φ〉 , 〈ψjφk〉) (11)
d 〈φ〉
dt
= g
(〈ψ〉 , 〈φ〉 , 〈ψjφk〉)
with j, k = 1, 2.
These equations can be studied numerically by assuming uncorrelation and very small
standard deviations in the deterministic part. These hypotheses can be written as follows:
〈ψφ〉 ' 〈ψ〉 〈φ〉 , 〈φ2〉 ' 〈φ〉2 , 〈ψ2〉 ' 〈ψ〉2 (12)
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Based in the analytical treatment, the next equations were found:
d 〈ψ〉
dt
= b1 〈ψ〉 − (b1 + c12) 〈ψ〉 〈φ〉 − (b1 + c11)
〈
ψ2
〉−Q1 (〈ψ〉+ ε 〈φ〉)
d 〈φ〉
dt
= (b2 − d2) 〈φ〉 − b2 〈ψ〉 〈φ〉 − b2
〈
φ2
〉− c21 〈ψ2〉 〈φ〉 −Q1 (〈ψ〉+ ε 〈φ〉)
We have solved numerically this system of coupled nonlinear differential equations and
two basins were found: one where the patient survives (health basin) plus other where he
dies. We have accepted these results because the well-known medical evidence is reproduced.
Besides, time evolution of the cancer cell density can be explored from the first equation.
To do that, we write it as
d 〈ψ〉
dt
= b1 〈ψ〉
{
1− 1
KL
〈φ〉 − 1
Kc
〈ψ〉
}
−Q1 (〈ψ〉+ ε 〈φ〉)
where
Kc =
1
1 + c11
b1
and
KL =
1
1 + c12
b1
Logistic growth is the particular case where there is no chemotherapeutic treatment and
lymphocytes are not present. For this reason we put Q1 = 0, and 〈φ〉 = 0. Then
d 〈ψ〉
dt
= b1 〈ψ〉
{
1− 1
Kc
〈ψ〉
}
and a stationary state can be reached because limt→∞ 〈ψ〉s = Kc. Therefore Kc is the
carrying capacity of the population of cancer cells.
However, lymphocytes are an important part of the system and they play a fundamental
role in the defense of the patient. So that it is necessary to see what happens in the
healthy basin. This can be explored by assuming a case where successful chemotherapeutic
treatment has been applied and retired with good results. We put Q1 = 0, and 〈φ〉s ' 1,
because almost all the available spaces are occupied by lymphocytes. Now the solutions are
〈ψ〉(1)s ' 0
and
〈ψ〉(2)s ' Kc
(
1− 1
KL
)
= −c12
b1
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But densities cannot be negative, so that 〈ψ〉(2)s is not acceptable. As a consequence, from
a macroscopic point of view, like in medical diagnosis, health has been recovered.
However there is a hidden problem. In the stochastic case densities are
ψ = 〈ψ〉+ η, φ = 〈φ〉+ ξ
Denoting the random fluctuations as (η, ξ) = (q1, q2) = ~q, the time dependent Ornstein-
Uhlenbeck process obeys the following Fokker-Planck equation
∂Π (~q, t)
∂t
= −
2∑
µ=1
∂ [Aµ (〈ψ〉 , 〈φ〉 , ~q) Π (~q, t)]
∂qµ
+
1
2
2∑
µ=1
2∑
ν=1
∂2 [Dµν (〈ψ〉 , 〈φ〉 , ~q) Π (~q, t)]
∂qµ∂qν
(13)
with
{Aµ} =
 A1
A2
 = L (〈ψ〉 , 〈φ〉) ~q (14)
the flux term and L (〈ψ〉 , 〈φ〉) the matrix convection. The diffusion matrix is given as
{Dµν} =
 D11 (〈ψ〉 , 〈φ〉) D12 (〈ψ〉 , 〈φ〉)
D12 (〈ψ〉 , 〈φ〉) D22 (〈ψ〉 , 〈φ〉)
 = D (15)
Since the random part depends on the deterministic one, the process is named a nonau-
tonomous system. Correlations are defined as
{Ξµν} = {〈qµqν〉 − 〈qµ〉 〈qν〉} = Ξ, (16)
and satisfy the differential equations written by van Kampen [26]:
dΞ
dt
− LΞ−ΞL = D (17)
The solution to (13) is a Gaussian function given as
Π (~q, t) =
1√
2pi
√
det Ξ
exp
{
−1
2
[~q − 〈~q〉 (t)] ·Ξ−1 [~q − 〈~q〉 (t)]
}
(18)
Using that Ξ12 = Ξ21, the vector ~z is defined as
~z =

Ξ11
Ξ12
Ξ22

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and the system (17) can be written as
d~z
dt
= A~z + ~d
with A a matrix whose components depend on time through the pair {〈ψ〉 , 〈φ〉}. The
trivector ~d contains the diffusion. This expression has been used to analyze the case 〈φ〉s ' 1
and 〈ψ〉s ' 0, founding that the eigenvalues of the matrix A take positive values; then, the
time-evolution of zi (t) is not bounded. This suggest that a possible noise-induced escape
from health basin could be hidden here.
In summary, the analytical approach give us the next conclusions:
1. The deterministic part is divided in two basins: one of healthy patient, with final
states near (0, 1); and other one for death patients, such that the final state is near
(1, 0).
2. The random part is such that fluctuations could maintain instability in final states,
such that healthy patients are in risk.
However, this analytical approach cannot help us to explore the last conclusion, because
these time dependent Ornstein-Uhlenbeck stochastic processes are useful for small fluctua-
tions, and since these goes like ∼ N− 12 , small populations result unreachable. So, we have
to consider that this simulation approach is necessary to include any number of cancer cells
and lymphocytes and without the hypothesis (12).
D. Algorithm for computer simulation
Once transition rates and events are available, Doob and Gillespie algorithm can be
applied to get the simulations [27]. This was done taking into account a software developed
by Th. Newman [28, 29]. The original problem in Gillespie paper consists in a chemical
system confined in a volume V and evolving on time, such that it can be specified by M
state variables h1, h2, ..., hM , with hµ being the number of different molecular reactants
combinations for each reaction Rµ. (µ = 1, ...,M). Obviously, there should be transition
rates specified (please see [30]). In our paper, these transition rates are built by using
elementary probability (see Table 3).
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Gillespie approach considers a reaction probability density function P (τ, µ), such
that P (τ, µ) dτ is the probability, at time τ , that a reaction will occur in the interval
(t+ τ, t+ τ + dτ). He followed a reasoning similar to the one expressed to study the proba-
bility of collisions in gases [31]. First, he considered the probability P0 (τ) that no reaction
occurs in the interval (t, t+ τ). Second, it was taken into account the probability hµcµdτ ,
to first order in dτ , that a reaction Rµ occurs in the interval (t+ τ, t+ τ + dτ). If the no
overlapping intervals are statistically independents, the probability that there is no reaction
in the interval (t, t+ τ), but there is a reaction at (t+ τ, t+ τ + dτ), is
P (τ, µ) dτ = P0 (τ)hµcµdτ (19)
Then, he found that the density probability P (τ, µ) is given as
P (τ, µ) = hµcµe
−∑Mν=1 hνcντ (20)
As a consequence, a stochastic process described by the transitions given at Table 3 can
be simulated, according to Gillespie, with the following algorithm. Here it is named as a
one urn model of no spatial cancer cells and lymphocytes:
Step = 0: Initialization
The number Ω of objects in the urn is generated. This is the number of sites in the line
of battle of our paper.
The number of realizations N0 is specified. N0 = 1 in the historical mode, or N0 ∼ 104
in the final mode.
Transition rates are introduced: σi, i = 1, ..,M , with M the number of interactions
between two species.
Initial time t = 0 is set.
The initial number of cancer cells NA (0), and lymphocytes NB (0), are specified. Store
(t, NA, NB).
The variable sigma sum = 0 is set.
Step = 1: Iteration
1. Produces an actualization of the variable sigma sum as follows:
sigma sum =
M∑
i=1
σ (i) (21)
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2. Generates two random numbers r1 and r2, with homogeneous probability in [0, 1].
3. Creates time increment
τ =
1
sigma sum
ln
(
1
r1
)
(22)
This gives us a random τ with exponential distribution.
4. Actualizes the time t→ t+ τ .
5. Random number r2 is used to choose one of the M interactions.
6. Actualizes NA and NB according to the event chosen in 5.
7. Stores (t+ τ,NA, NB) and go to 1.
III. RESULTS AND DISCUSSION
Our simulation of the line of battle in an avascular tumor, described above, was developed
considering the following fixed parameters: b1 = 0.35, b2 = d2 = 0.078, and c12, c21, c11;
and d1 changing such that real behavior reproduced in medical practice can be simulated.
However, since we are dealing with the simulation in a line of battle, an estimation of real
time cannot be obtained at this stage of the model. We must recognize that this is a problem
under consideration right now, for example, some authors have presented reasons to think
that development of big tumors is exponential at first, but polynomial after that [32].
The simulation produces the next results:
A. Checking the algorithm
At first, the approach was checked by working with b1 = d1 = 0.35, and the others param-
eters equal to zero. Initial conditions where: Ω = 6250, N (t = 0) = 625 and M (t = 0) = 1.
Algorithm was run in two modes: in the first one the time evolution is saved to a file (his-
torical mode), and in the second one just the final data are saved to a file once a time has
been reached (final results mode). The historical mode is presented in figure 3.
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Figure 3
In the final results mode 104 data were generated, then, mean and standard deviation
were evaluated to obtain:
〈N〉 = 591.625, σN = 23.9466,
where 〈N〉 and σN are taken on the sample of data obtained.
A similar work was done to see the behavior of lymphocytes when b2 = d2 = 0.078,
and the rest of parameters equal to zero. Here the initial conditions were: Ω = 6250,
N (t = 0) = 1, and M (t = 0) = 625. The historical mode gives us a graph presented in
figure 4.
Figure 4
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After that, the final results mode was used to generate 104 data. Mean and standard
deviation gave us:
〈M〉 = 617.166, σM = 12.0828
B. Development without specialized defense
Here we will consider two different systems. In one of them, sentinel macrophages are
activated when tissue homeostasis is perturbed, so that soluble mediators are released, like
cytokines, chemokines, matrix remodeling proteases and reactive oxygen species, bioactive
mediators such as histamine to induce mobilization and infiltration of additional leukocytes
into damaged tissue. The other one is a more sophisticated adaptive immune system de-
veloped through direct interaction with mature antigen-presenting cells where the adaptive
immune cells are involved, like B lymphocytes, CD4+ helper T lymphocytes and CD8+
cytotoxic lymphocytes [33]. Both systems, specialized, and non-specialized defense, are
simulated ahead.
First we simulate the case of a sick patient without medical treatment, this is done by
taking the following initial conditions: Ω = 6250, N (t = 0) = M (t = 0) = 625. Regime of
a sick person without medical attention was simulated by using the parameters: b1 = 0.35,
b2 = d2 = 0.078, with c12 = c21 = c11 = d1 = 0. Historical mode gives us the graph shown
in figure 5.
Figure 5
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Using the final data mode, we developed 104 realizations to evaluate the mean and the
standard deviation of cancer cells in the time needed to take the number of lymphocytes
down to zero. This is
Number Volume (µm)3
〈N〉 6248.72 1.67517× 106
σN 0.596 1.598
Average time and its standard deviation is presented in algorithmic time and its translation
to days is done by dividing by the number of available spaces Ω = 6250.
Algorithmic time days
〈t〉 537657 86.02
σt 63530 10.16
This can be interpreted in the sense that cancer cells prevail because the cancer cells of
the line of battle are successful to produce, in 86 days, a growing tumor whose extension
is added in a volume of 1.67517 × 106 (µm)3. Obviously the action of lymphocytes is not
enough.
C. Development with immune response (specialized defense)
The immune specialized response is simulated by considering the same initial conditions
used in the previous subsection. It is a regime of a sick person without medical attention
but with good immune response, and the parameters used were: b1 = 0.35, b2 = d2 = 0.078,
with c12 = 1× 10−5, and c21 = c11 = d1 = 0.
Historical mode gives us the graph shown in figure 6:
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Figure 6
We find that by increasing the specialized defense against cancer cells, the lymphocytes
prevail on the line of battle in just 300 unites of algorithmic time. If one has 25 layers of
cancer cells, 7500 units of algorithmic time would be enough. This result suggests three
reflections:
1. According to this model, colonies of cancer cells could appear on the organism fre-
quently, but they would be destroyed before a tumor can reach a critical radius to
start metastasis.
2. A tumor grows enough, and appears with a critical radius, due to the absence of a
specialized defense where the enemies (cancer cells) are clearly identified and a specific
kind of lymphocytes are produced and directed against.
3. A tumor with a critical radius appears just when a barrier is opposed to blood flux
and lymphocytes do not get touch with cancer cells.
The final data mode was developed by simulating 104 realizations to evaluate the mean
and the standard deviations of lymphocytes in the time needed to take the number of cancer
cells down to zero. It was found that
Number
〈M〉 1251.34
σM 4.35
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Algorithmic time for 25 layers days
〈t〉 14840.9 2.374
σt 2474.47 0.396
In attention to the third reflection, we can cite a review by Tre´dan et. al. [34]. They have
discussed that the effectiveness of drug therapy is impaired by limited delivery of drugs to
some regions of tumors. So, we can think that similar results should be true for the action
of specialized defense of the body, such that if cancer cells survive, it is because they are
not in touch with lymphocytes.
D. Development with specialized defense and a weak patient
We consider the same condition in immune specialized response, but now with a patient
whose production of lymphocytes is diminished due to proliferation of cancer cells. This was
simulated by using the parameters: b1 = 0.35, b2 = d2 = 0.078, c12 = 1× 10−5, and c21 = 1,
while c11 = d1 = 0.
Historical mode gives us the graph of figure 7.
Figure 7
It is found that specialized defense against cancer cells gives good results, even in the case
of weakness in patients. This is corroborated by using the final data mode. We simulate
104 realizations to obtain the mean and the standard deviations of lymphocytes in the time
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needed to take the number of cancer cells down to zero. The results are
Number
〈M〉 1251.34
σM 4.35
Algorithmic time for 25 layers days
〈t〉 14858 2.378
σt 2507.93 0.401
E. Development with a lot of lymphocytes but non-specialized defense
This is a strategy where reproduction rate of lymphocytes grow but in a general sense,
without acting through the transition: B + A → B + B. This is done with the following
values of the parameters: b1 = 0.35, b2 = 1, d2 = 0.078, c12 = c21 = c11 = d1 = 0. Results
are shown in figure 8.
Figure 8
With the parameters b1 = 0.35, b2 = 1.5, d2 = 0.078, c12 = c21 = c11 = d1 = 0, the graph
obtained is shown in figure 9.
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Figure 9
And with the parameters b1 = 0.35, b2 = 2, d2 = 0.078, c12 = c21 = c11 = d1 = 0, the results
are shown in figure 10.
Figure 10
We found that even with a big amount of lymphocytes, good results are not reached. The
absence of specialized lymphocytes produces fatal results.
F. Strategy based on anti-angiogenic drugs. self-competition in cancer cells
A new broad family of anticancer drugs has been approved in recent years. These are
angiogenesis inhibitors administrated to avoid the building of new blood vessels going from
25
the main blood flow to the region where the tumor has born. They can inhibit the produc-
tion of angiogenic proteins, neutralize angiogenic proteins or inhibit receptors where these
proteins are received. Some drugs induce endothelial cell apoptosis.
The general effect of these new drugs is to restrict, in some way, the flow of oxygen
and nutrients to the tumor. So, this is analog to the situation of a colony of bacteria in
a recipient with a finite capacity of oxygen and nutrients. This is modeled in an approach
named ”logistic growth”, where a quadratic term is added ad hoc to introduce a control in
the, otherwise, exponential growth. The number of bacteria in the recipient is stabilized
because they are competing for food.
This is the case in cancer cells when they are in the core of a tumor, so that blood
flow does not arrive there and necrotized tissue appears as a consequence. However, in the
line of battle is totally different, because there is a lot of blood there, so that reproduction
is possible. Our idea is to avoid all the complex details involved in the process produced
by anti-angiogenic drugs, to model their effect as one where oxygen and nutrients are not
enough, even in the surface of the tumor. So, the effect of antiangiogenic drugs is modeled
through the constant c11, as self-competition between cancer cells looking for oxygen and
nutrients running out. It is the transition: A+ A→ A+ E.
Working with the parameters b1 = 0.35, b2 = d2 = 0.078, c12 = c21 = d1 = 0, and
c11 = 1× 10−5, and using the historical mode, we found the graph shown in figure 11.
Figure 11
Figure 11 is very important because contains two interesting results:
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First: we can see that number of cancer cells in the line of battle goes to zero, however,
the amount of lymphocytes goes down to a very dangerous level. This is an unexpected con-
sequence because any transition rate of this model is considering side effects. We have found
in the literature that anti-angiogenic therapy could cause several toxicities and biological
effects, please see reference [35].
Second: cancer cells go to zero after a very long time with very small random fluctuations.
At a first glance, medical treatment can be retired because macroscopic manifestations
cannot be detected. However, this is precisely the regime that we could not solve with our
analytical approach. A regime with unbounded standard deviations. We will see in the next
subsection what happens in this case.
G. Released patients under macroscopic considerations
By observing figure 11 we could think that it is better to withdraw a treatment when the
number of lymphocytes is of the order of 400, before they reach a dangerous level. We have
modeled that option by starting from the initial conditions N (t = 0) = 3 and M (t = 0) =
625, with the parameters b1 = 0.35, b2 = d2 = 0.078, with c12 = c21 = c11 = d1 = 0. The
historical mode gives us the results shown in figure 12.
Figure 12
Even for small values of the number of cancer cells, we found fatal results. So, an
important prediction of the model is that there is only one option: to take the number of
cancer cells down to zero.
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In this dormant state there is no clinical or radiological evidence, because the number of
malignant cells is very low, thus its reproduction and organic dissemination rates are low
too. But there already are mutations associated with malignant processes that are detected
with ultrasensitive molecular methods. See for example [36].
H. Induced apoptosis in cancer cells
Induced apoptosis of cancer cells is introduced with the constant d1 in order to model
the action of the Cuban drug Vidatox 30 CH, as reported by A. Dı´az et. al. [37]. They
wrote that venom of the scorpion Rhopalurus Junceus caused the cellular death through the
apoptosis in tumor cells. It is the transition A→ E, and was simulated with the parameters
b1 = 0.35, b2 = d2 = 0.078, with c12 = c21 = c11 = 0, and d1 = {0.1, 0.2, 0.3, 0.4, 0.5}. The
historical mode gives us the results shown in figures 13 to 17.
Figure 13
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Figure 14
Figure 15
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Figure 16
Figure 17
We have found that induced apoptosis gives us good results provided that the parameter
takes higher values. It can be seen that the amount of lymphocytes is higher than 400 with
the values of the parameter d1 = 0.4, 0.5.
I. Combining anti-angiogenic drugs and induced apoptosis in cancer cells
Now we can review what happen if anti-angiogenic and inducer apoptosis drugs are
combined.
The historical mode gives us the results shown in figure 18.
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Figure 18
Here the number of cancer cells goes to zero, when the number of lymphocytes is higher
than the obtained in the strategy based on anti-angiogenic drugs. A specific detail was
analyzed by using the final data mode: we developed 104 realizations with the parameters
b1 = 0.35, b2 = d2 = 0.078, with c12 = c21 = 0, and c11 = 1 × 10−5, d1 = 0.1. As was
presented above, the results with c11 = 1× 10−5 are positive, but with a dangerous amount
of lymphocytes. Besides, d1 = 0.1 does not produce good results. On the contrary, if both
of them are combined, the number of cancer cells goes to zero with the following mean and
standard deviations for time and number of lymphocytes:
Number
〈M〉 501.18
σM 80.26
Algorithmic time for 1 layer
〈t〉 218320
σt 170917
It can be seen that standard deviation is too large, 78.29% of the mean. As we have found
before, this kind of random behavior is higher in the change from fatal results to healthy
patients. To review that, we developed 104 realizations in the final data mode, with the
parameters: b1 = 0.35, b2 = d2 = 0.078, with c12 = c21 = 0, but c11 = 1 × 10−4, d1 = 0.2.
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After the statistical analysis we found
Number
〈M〉 613.65
σM 15.86
Algorithmic time for 1 layer
〈t〉 14663.1
σt 8941.89
The number of lymphocytes is higher in 22.44% than in previous case; besides, time is
shorter and its standard deviation has diminished to 60.98% of the mean time.
Then, one important conclusion of this work is that efficiency is enhanced with a combi-
nation of anti-angiogenic drugs plus a system based in artificial apoptosis of cancer cells.
While some reticence against induced-apoptosis in cancer cells exists, as an option to
obtain successful anti-cancer drugs, it must be recognized that it is a mechanism strongly
considered right now. Favorable opinions can be found in [38].
IV. CONCLUSIONS
The results obtained in this work allow us to discuss the following:
• This model predicts that cancer can relapse from a very small number of cancer cells
due to the existence of unbounded standard deviations.
• Specialized immune response of a living being is definitely crucial in fighting cancerous
tumors.
• Even in the case of a weakened patient, sufficient production of specialized leukocytes
may be decisive in the survival of the organism.
• When the body does not have specialized leukocytes, its capacity to deal with the
problem of a cancerous tumor is very limited, and the prognosis is unfortunately
death.
• The use of anti-angiogenic drugs is a strategy that can be used to remove cancerous
tumors. However, they also affect the rest of the body; they can weaken and place in
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a fragile state to the patient before the attack of other possible diseases. Furthermore,
if the cancer cells are not eliminated, there is a high probability that they re-grow in
number, and again the result is fatal.
• A strategy based on a novel drug that causes apoptosis of cancer cells shows great
potential in fighting cancerous tumors, but it also produces some weakening of the
body.
• The combination of strategies seems to be a better alternative because it could pro-
duce a very rapid decrease in cancer cells, reducing the amount of medication to be
administered and therefore would be less side effects.
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